Bruker Corporation announced the appointment of Dr. Eicke Latz to its Board of Directors, effective January 1, 2027. The Board approved an increase in its size from eleven to twelve directors, with the new seat assigned to Class II. Dr. Latz will initially serve on the board until the 2029 Annual Meeting of Stockholders.

Dr. Latz is a physician-scientist and biopharma entrepreneur. He currently serves as the Scientific Director of the German Rheumatology Research Center (DRFZ) and Professor of Experimental Rheumatology at Charité Universitätsmedizin Berlin. Previously, he founded and directed the Institute of Innate Immunity at the University of Bonn.

According to the company, Dr. Latz has co-founded five biotechnology companies, including IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics, and Beren Therapeutics. His work focuses on translating discoveries in innate immunity and inflammation into therapeutic approaches, with programs advancing into clinical development.

Bruker’s Chairman, President, and CEO Frank H. Laukien stated that Dr. Latz brings a combination of disease biology leadership and biopharma entrepreneurial success to the company. Dr. Latz expressed his honor in joining, noting his view of Bruker as a leader in AI-accelerated deep functional proteomics and spatial biology research.

In other business, the Board declared a quarterly cash dividend of $0.05 per share on the Company’s common stock. The dividend was declared on November 12, 2026, and is payable on January 7, 2027, to shareholders of record as of the close of business on December 21, 2026.